Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma

Table 2

Univariate logistic regression analysis of clinicopathological variables associated with CK19 status in hepatocellular carcinoma.

Variable	OR (95% CI)	value
Gender (male vs. female)	1.22 (0.24-6.26)	0.81
Age (<60 vs. ≥60 years)	0.49 (0.15-1.61)	0.24
HBV infection (no vs. yes)	0.57 (0.16-2.01)	0.38
Cirrhosis status (no vs. yes)	1.48 (0.55-3.99)	0.44
ALBI grade (grade 1 vs. grade 2)	0.63 (0.23-1.71)	0.37
MELD score (<9 vs. ≥9)	1.22(0.24-6.26)	0.81
Tumor size (<5 vs. ≥5 cm)	1.60 (0.59-4.36)	0.35
AST (<40 vs. ≥40 U/L)	1.00 (0.32-3.06)	1.00
ALT (<40 vs. ≥40 U/L)	1.54 (0.54-4.36)	0.42
PT (<12.1 vs. ≥12.1 sec)	0.55(0.17-1.77)	0.32
Platelet (<125 vs. /L)	0.60 (0.19-1.90)	0.38
Serum AFP (<400 vs. ≥400 ng/mL)	5.38 (1.88-15.34)	<0.001
Serum CA 19-9 (<34 vs. ≥34 U/mL)	0 (0-Inf)	0.99
Serum CEA (<5 vs. ≥5 ng/mL)	0.45 (0.05-3.74)	0.46

. AFP: alpha fetoprotein; ALBI: albumin-bilirubin grade; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CA 19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CI: confidence interval; HBV: hepatitis B virus; MELD score: Model for End-Stage Liver Disease score; OR: odds ratio; PT: prothrombin time.